PSTV · Plus Therapeutics, Inc.
$3.92
+0.09 (+2.35%)
At close · Jul 21
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$26.98M
Shares
6.88M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$5.21M
-10.5%
FY2025
Net Income
-$22.39M
-72.5%
FY2025
Gross Margin
5.43%
-36.3pp
FY2017
Operating Margin
-293.46%
-41.1pp
FY2025
Diluted EPS
-$7.25
+87.6%
FY2025
Operating Cash Flow
-$20.78M
-96.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $5.18M | $5.21M | $5.82M | $4.91M | — | — | — | — | $3.67M | $2.69M | $4.66M | $4.84M | $4.95M | $7.12M | $8.71M | $7.98M | $8.25M | $5.84M | |
| — | — | — | — | — | — | — | — | $1.15M | $1.32M | $2.72M | $3.19M | $2.94M | $3.42M | $4M | $3.84M | $3.91M | $3.39M | |
| $441K | — | — | — | — | — | — | — | — | $146K | $1.94M | $1.65M | $2.01M | $3.7M | $4.71M | $4.15M | $4.35M | $2.44M | |
| — | — | — | — | — | — | — | — | — | 5.43% | 41.69% | 34.15% | 40.64% | 51.97% | 54.07% | 51.94% | 52.65% | 41.85% | |
| $9.49M | $8.38M | $10.58M | $9.69M | $9.7M | $5.32M | $2.7M | $5.37M | $5.52M | $11.68M | $16.2M | $19M | $15.11M | $17.07M | $13.63M | $10.9M | $9.69M | $12.23M | |
| $482K | — | — | — | — | — | — | $468K | $643K | $3.59M | $3.61M | $2.66M | $6.41M | $9.03M | $9.49M | $13.56M | $11.04M | $6.58M | |
| $14.58M | $12.13M | $9.94M | $8.54M | $10.24M | $6.85M | $6.41M | $5.29M | $5.58M | $7.59M | $8.56M | $9.77M | $15.95M | $16.03M | $15.67M | $14.73M | $12.57M | $10.42M | |
| — | $100K | $100K | $100K | $100K | $32K | — | — | $1.25M | $1.24M | $584K | $397K | $185K | $49K | $192K | $221K | — | — | |
| — | $445K | $872K | $628K | $619K | $395K | $366K | $896K | $2M | $2.15M | $1.18M | $1.09M | $779K | $1.63M | $933K | $855K | $931K | $1.68M | |
| $24.06M | $20.51M | $20.52M | $18.23M | $19.94M | $12.49M | $9.89M | $10.66M | $11.75M | $24.55M | $28.37M | $23.76M | $37.1M | $39.45M | $38.92M | $35.57M | $32.04M | $32.88M | |
| -$18.88M | -$15.3M | -$14.7M | -$13.32M | -$19.71M | -$12.49M | -$9.58M | -$3.66M | -$8.76M | -$20.68M | -$19.71M | -$15.29M | -$32.44M | -$30.68M | -$28.42M | -$29.41M | -$25.32M | -$21.55M | |
| — | -293.46% | -252.32% | -271.14% | — | — | — | — | -238.68% | -769.17% | -423.24% | -315.96% | -654.9% | -430.76% | -326.31% | -368.43% | -306.8% | -369.15% | |
| — | -$14.85M | -$13.82M | -$12.69M | -$19.09M | -$12.1M | -$9.22M | -$2.76M | -$6.76M | -$18.53M | -$18.52M | -$14.19M | -$31.66M | -$29.05M | -$27.49M | -$28.56M | -$24.39M | -$19.87M | |
| — | $548K | $179K | $395K | $711K | $932K | $1.11M | $1.86M | $1.92M | $2.05M | $2.59M | $3.38M | $4.37M | $3.4M | $3.39M | $2.78M | $2.05M | $1.43M | |
| $305K | $116K | $273K | $400K | $147K | $19K | $50K | $55K | $43K | $33K | $19K | $9000 | $6000 | $4000 | $4000 | $9000 | $9000 | $20K | |
| $6.95M | -$7.09M | $1.72M | $5000 | -$563K | -$907K | $1.34M | $374K | -$116K | -$2M | -$2.34M | -$3.46M | -$4.93M | $4.5M | -$3.86M | -$3.04M | -$2.17M | -$1.67M | |
| — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | -$48K | -$165K | -$209K | -$151K | -$44K | |
| — | -$22.39M | -$12.98M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — | — | |
| -$11.93M | -$22.39M | -$12.98M | -$13.32M | -$20.28M | -$13.4M | -$8.24M | -$10.89M | -$12.63M | -$22.69M | -$22.05M | -$18.74M | -$37.37M | -$26.18M | -$32.28M | -$32.45M | -$27.49M | -$23.22M | |
| — | -429.43% | -222.84% | -271.04% | — | — | — | — | -344.16% | -843.66% | -473.5% | -387.43% | -754.45% | -367.55% | -370.64% | -406.5% | -333.1% | -397.74% | |
| — | — | — | — | — | — | -$8.24M | -$11.44M | -$15.12M | -$26.66M | -$22.05M | -$19.41M | -$38.54M | -$26.18M | -$32.28M | — | — | — | |
| -$8.68M | — | — | — | — | — | — | -$10.89M | -$12.8M | -$22.56M | -$21.78M | -$18.45M | -$36.92M | -$25.92M | -$32.28M | -$32.45M | — | — | |
| USD/shares | — | -$7.25 | -$48.75 | -$106.00 | -$289.50 | -$416.25 | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$7.25 | -$58.50 | -$106.00 | -$289.50 | -$416.25 | — | — | — | — | — | — | — | — | — | -$228.75 | -$225.00 | -$243.75 |
| shares | — | 3.11M | 265.61K | 125.64K | 70.01K | 32.24K | 11.81K | 3690.6987 | 463.6027 | 8637.288 | 46.11K | 25.03K | 215.55K | 180.75K | 156.48K | 142.68K | 122.53K | — |
| shares | — | 3.11M | 308.03K | 125.64K | 70.01K | 32.24K | 11.81K | 3690.6987 | 463.6027 | 8637.288 | 46.11K | 25.03K | 215.55K | 180.75K | 156.48K | 142.68K | 122.53K | 95.84K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
0.18×
Biotechnology median 7.21×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2023 | FY2022 |
|---|---|---|
| Grant | $4,913,000 | $224,000 |